|
Oct 9
|
Lipocine signs supply and distribution agreement with Pharmalink for Tlando
|
|
Oct 8
|
Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries
|
|
Oct 2
|
Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024
|
|
Aug 27
|
Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference
|
|
Jun 25
|
Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study
|
|
May 9
|
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024
|
|
May 8
|
Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024
|
|
May 1
|
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154
|
|
Apr 11
|
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
|
|
Mar 28
|
Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis
|
|
Mar 25
|
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
|
|
Mar 7
|
Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
|
|
Mar 6
|
Lipocine to Present at 36th Annual Roth Conference
|
|
Feb 2
|
Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals
|
|
Dec 19
|
Lipocine to Present at Biotech Showcase 2024
|
|
Nov 13
|
Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023
|
|
Nov 8
|
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023
|
|
Aug 10
|
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023
|